Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple t...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Zizzari, Ilaria, Mazzuca, Federica, Ascierto, Paolo Antonio, Putignani, Lorenza, Marchetti, Luca, Napoletano, Chiara, Nuti, Marianna, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352451/
https://www.ncbi.nlm.nih.gov/pubmed/27806346
http://dx.doi.org/10.18632/oncotarget.12985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352451/
https://www.ncbi.nlm.nih.gov/pubmed/27806346
http://dx.doi.org/10.18632/oncotarget.12985

Ejemplares similares